Anastrozole vs Halotestin
FDA Approved vs Well Studied
avoid Mechanism-based · 64% Both Anastrozole and Halotestin carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Anastrozole Halotestin
Weight 293.37 Da 336.44 Da
Half-life ~40-50 hours ~9.5 hours
Type Nonsteroidal aromatase inhibitor (triazole derivative) 9-fluoro-11-beta-hydroxy-17-alpha-methyltestosterone (C20H29FO3)
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
Halotestin
01 Dramatic increase in strength and power output without water retention
02 Pronounced increase in aggression and competitive drive
03 Does not aromatize to estrogen, producing a hard and dry appearance
04 Enhances red blood cell production and oxygen-carrying capacity
05 Rapid onset of effects, typically noticeable within days
06 Uniquely suited for pre-competition or pre-meet peaking protocols
07 Short cycle duration limits cumulative exposure
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
Halotestin
Severe hepatic stress (elevated ALT, AST, GGT, bilirubin)
Pronounced aggression and irritability
HDL cholesterol suppression and LDL elevation
Elevated blood pressure
Headaches (frequently reported, may be related to blood pressure changes)
Suppression of endogenous testosterone production
Oily skin and acne
Decreased appetite (potentially related to liver stress)
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Known or suspected prostate cancer
Breast cancer in males
Pregnancy (Category X - causes fetal harm)
Active liver disease or existing hepatic impairment
Severe cardiovascular disease or uncontrolled hypertension
Hypercalcemia
Nephrosis or nephrotic phase of nephritis
History of cholestatic jaundice or hepatic dysfunction from prior anabolic steroid use
Hypersensitivity to fluoxymesterone or any formulation component
Research Evidence
Anastrozole Halotestin
Status FDA Approved Well Studied
References 5 studies 5 studies
Latest — October 2023
FDA Approved Yes Yes
More comparisons: Testosterone
This comparison is for educational and research purposes only. Consult a healthcare professional before use.